Drug Profile
Research programme: gastrointestinal disease therapeutics - Altos Therapeutics
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Altos Therapeutics
- Class
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Gastrointestinal disorders in USA (unspecified route) (Takeda pipeline, March 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA
- 01 Jul 2016 Altos Therapeutics enters into a definitive agreement with Takeda that includes an exclusive option for Takeda to acquire Altos